This study aimed to detect differences in mitochondrial proteins in eutopic endometrial samples from women with adenomyosis (n = 13) and endometriosis (n = 24), and from control patients (n = 29) using surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry (SELDI-TOF-MS) protein chip technology. A total of 82 and 78 mitochondrial protein peaks were found in adenomyosis and endometriosis individuals, respectively. Of these, 14 were common to women with adenomyosis and women with endometriosis, although only one of these (mass-to-charge [m/z] ratio 3499) was significantly different between the adenomyosis and endometriosis groups. It is concluded that, compared with control patients, there are differences in the mitochondrial proteins isolated from the eutopic endometrium of patients with adenomyosis and those with endometriosis. Although the changes in mitochondrial proteins in eutopic endometrium from patients with adenomyosis and endometriosis were largely similar, significant differences were also detected. Further identification of these proteins and elucidation of the differences will help towards the differential diagnosis of adenomyosis and endometriosis and new therapeutic approaches.
Introduction
Endometriosis is a chronic condition characterized by the presence of endometrial tissue outside of the uterus in lesions of varying sizes and appearance containing endometrial glands and stroma. 1 X Ding, L Wang, Y Ren et al.
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Adenomyosis is characterized by, and is the result of, the invasion of basal endometrial glands and basal endometrial stroma into the underlying myometrium. 2 Despite significant improvements in understanding of the pathogenesis of endometriosis and adenomyosis, there is much that is still unclear. Adenomyosis is either considered a variant of endometriosis, widely referred to as 'internal endometriosis', 3 or is considered a distinct disease from endometriosis, requiring different therapeutic approaches. 4 The view that there are fundamental proteomic and genomic differences in the eutopic endometrium of women who develop endometriosis is now widely accepted. 5 To date, however, the role played by eutopic endometria in the development of adenomyosis is unclear.
Mitochondria play crucial roles in the metabolism of amino acids and lipids, the biosynthesis of haem and iron-sulphur clusters, cell signalling and apoptosis. 6 Research has indicated that mitochondria might be new markers for the early detection, risk assessment and diagnosis of cancer and other diseases, and for the identification of new targets for therapeutic prevention and intervention. 7 Although some proteins, such as vascular endothelial growth factor (VEGF) 8,9 and human leucocyte antigen-G, 10,11 are dysregulated in both adenomyosis and endometriosis, it is not known whether the same eutopic mitochondrial proteins are found in both endometriosis and adenomyosis.
Proteomics is a powerful technique for studying the protein profile of diseased and normal tissues and is a promising approach for discovering disease biomarkers and key proteins in pathogenesis. 12 Protein chip technology coupled with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) has offered a sensitive, high throughput and rapid way for screening protein expression within complex biological specimens. 13, 14 In a previous study, we identified five potential biomarkers in the serum of women with endometriosis using SELDI-TOF-MS protein chip array technology, and this diagnostic system was shown to distinguish endometriosis from validation samples with a sensitivity of 91.7% and a specificity of 90.0%. 15 The present study was designed to search for different mitochondrial proteins in samples of eutopic endometrium from patients with adenomyosis or endometriosis, and to compare the proteins between the two diseases. The women enrolled in the study were divided into three groups: group 0 underwent laparoscopy for infertility or benign indications, and were without clinical symptoms of endometriosis during the clinical examination or visible evidence of endometriosis during surgery; group 1 had adenomyosis; and group 2 had ovarian or pelvic endometriosis. The diagnoses for all patients was confirmed by pathological examination of biopsied tissue. None of the patients had received any anti-inflammatory or hormone treatment for ≥ 6 months before inclusion in the study and surgery. X Ding, L Wang, Y Ren et al.
Patients and methods

PATIENTS AND SAMPLE COLLECTION
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obtained from the uterus of each patient at the conclusion of surgery. These were blotted on surgical gauze, flushed repeatedly with sterile 10 mM phosphate-buffered saline (PBS), pH 7.4, until contaminating blood had been removed, dried on filter paper, snap-frozen in liquid nitrogen within 30 min of collection and stored at −80°C.
The mitochondria were extracted using a mitochondria isolation kit (KeyGEN Biotech, Nanjing, China). The mitochondria samples were suspended with lysis buffer containing 40 mM Tris-HCl pH 7.4, 7 mol/l urea, 2 mol/l thiourea, 4% (w/v) CHAPS, 10 mM dithiothreitol, 2 mM ethylenediaminetetraacetic acid and 1 mM phenylmethylsulphonyl fluoride 16 for 30 min at 4°C, with intermittent vortexing. The homogenates were centrifuged at 15 000 g for 45 min and the supernatants collected. The concentration of mitochondrial protein was determined by a Bradford protein assay kit (KeyGEN Biotech). The mitochondrial protein samples were stored at −80°C until further use.
CHIP CHOICE AND PREPARATION
The SELDI-TOF-MS (Protein Biological System-II [PBS-II] plus mass spectrometer reader) and CM10 protein chips (weak cation exchanger) were purchased from Ciphergen Biosystems, Fremont, CA, USA. Sinapinic acid (SPA) was purchased from Fluka Chemie, Buchs, Switzerland. All other reagents were purchased from Sigma-Aldrich, St Louis, MO, USA.
SELDI-TOF-MS ANALYSIS
The samples were thawed at 4°C, then 40 µl of each protein sample was added to a well of a 96-well cell culture plate and diluted with 60 µl sodium acetate (100 mM, pH 4). The samples were agitated on a platform shaker at 4°C for 2 min.
The CM10 chips were activated by adding 200 µl of sodium acetate, agitation for 5 min and then repeating this process. Diluted protein samples (80 µl) were applied to each spot of the bioprocessor (Ciphergen Biosystems) that contained the activated protein chip arrays. The bioprocessor was then sealed and agitated on a platform shaker for 60 min at 4°C. Excess diluted samples were discarded. The chips were then washed three times with 200 µl sodium acetate and a further twice with deionized water. Finally, the chips were removed from the bioprocessor and air dried. Prior to SELDI-TOF-MS analysis, 1 µl of a saturated solution of SPA at dilutions of 0.5 l/l of chloroacrylonitrile and 5 ml/l of trifluoroacetic acid were applied to each chip twice and the chips were again air dried. Chips were analysed by the PBS-II plus mass spectrometer reader. Data were obtained by averaging 144 laser shots with an intensity of 170, a detector sensitivity of 6, a high mass of 100 000 Da and an optimized range of 2000 -20 000 Da. Mass accuracy was calibrated against an all-in-one peptide molecular mass standard (Ciphergen Biosystems). The spectra were normalized to the total ion currents (all ion masses from ionized proteins between 2000 and 20 000 Da) for all samples and the mass-to-charge ratios (m/z) were calculated. Noise was then filtered from the spectra and peaks were detected with an automatic peak detection pass. Peak clusters were completed on secondpass peak selection (signal-to-noise ratio > 5 within a 0.3% mass window) and estimated peaks were added. These operations were performed using ProteinChip Software, version 3.1 (Ciphergen Biosystems).
STATISTICAL ANALYSIS
The experimental data were handled by the Zhejiang University Cancer Institute Protein Chip Data Analysis System (ZUCIPDAS, X Ding, L Wang, Y Ren et al.
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www.zlzx.net) which was designed by Jiekai Yu and includes data pre-processing and model building. The pre-processed data were used to established models. In this experiment, a nonlinear support vector machine (SVM) classifier was used with a radial based function kernel, a parameter γ of 0.6, and a cost of the constrain violation of 19 to discriminate the different groups. The diagnostic model was evaluated and validated by leave-one-out cross validation, which takes out one sample each time as the test set and keeps the remaining samples as the training set; the test is then repeated until each sample has been taken once as a test sample.
The significance of each peak in the experimental data was estimated by calculating the P-value from the Wilcoxon signed-rank test. The top 10 peaks with the smallest P-value were selected for further analysis. Combinations of the different peaks that had the highest accuracy in distinguishing different groups of data were selected as potential biomarkers. The SVM model with the highest Youden's index was selected as the model for detecting endometriosis. A P-value < 0.05 was considered to be statistically significant.
Results
PATIENTS
A total of 66 women were included in the study divided into three groups as follows: group 0 (controls; n = 29), age range 23 -46 years, mean ± SD age 38.4 ± 5.8 years; group 1 (adenomyosis; n = 13), age range 35 -47 years, mean ± SD age 41.7 ± 4.2 years; group 2 (ovarian or pelvic endometriosis; n = 24), age range 23 -45 years, mean ± SD age 35.2 ± 6.4 years. There were no significant differences in mean age between the three groups.
REPRODUCIBILITY
Accuracy and reproducibility are the most important features and the first step in developing successful SELDI-TOF-MS profiling data. To examine the variation in data collection between the protein chips used in this study, quality control samples (nine mitochondrial protein samples from one control patient) were applied to each chip in a random fashion. The coefficient of variance (CV) for peak intensity was calculated using 10 randomly chosen peaks with a signal-tonoise ratio > 5 and m/z < 20 000. The CV of the selected peaks, after being normalized by intensity, was 15.2% and the CV of the selected peaks' mass was 0.03%. There was little variation with day-to-day sampling and instrumentation or chip variation.
EUTOPIC ENDOMETRIUM FROM WOMEN WITH ADENOMYOSIS
A total of 82 peaks were selected after noise filtering and peak cluster identification. There was a significant difference for one of the 82 peaks, at m/z 3366, between the samples from women with adenomyosis and those from controls (P = 0.039). There were no significant differences for the other 81 peaks. A total of 42 samples as a leave-one-out cross-validation test set were analysed to test the performance of the diagnostic model. The model showed three potential biomarkers, with m/z 7614, 14 978 and 6370. The m/z 7614 and 14 978 peaks had a higher level of expression in adenomyosis individuals but a significantly lower level of expression in controls. The specificity and sensitivity of the validation tests were 93.1% and 83.8%, respectively.
EUTOPIC ENDOMETRIUM FROM WOMEN WITH ENDOMETRIOSIS
A total of 78 peaks were selected after noise filtering and peak cluster identification. Of these, 10 peaks showed significant differences between the samples from patients with endometriosis and those from X Ding, L Wang, Y Ren et al.
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controls (Table 1 ). The differential model showed three potential biomarkers, with m/z 15 334, 15 128 and 16 069. All three peaks had a higher level of expression in endometriosis individuals. The specificity and sensitivity of the validation tests were 86.2% and 87.5%, respectively.
PEAKS COMMON TO WOMEN WITH ENDOMETRIOSIS AND ADENOMYOSIS
A total of 14 peaks were found in both groups ( Table 2) . Of these only the m/z 3499 peak showed a significantly different intensity between the patients with adenomyosis and those with endometriosis (P = 0.029). The other 13 peaks were not significantly different between the two groups.
Discussion
A previous study demonstrated that eutopic endometrium from women with endometriosis may have significant biochemical and ultrastructural differences compared with normal control tissue. 17 In addition, previous proteomic techniques have been used to screen and identify eutopic endometrial proteins that were expressed differently in patients with endometriosis versus normal controls. 18, 19 In the present study, 82 protein peaks were identified in eutopic mitochondrial protein samples from individuals with adenomyosis and 78 in samples from individuals with endometriosis. Eleven of these were significantly different from controls (10 for endometriosis patients versus controls and one for adenomyosis versus controls). This lends further supports to the idea that there are differences between the eutopic endometrium of patients with adenomyosis and endometriosis compared with that of healthy controls. It could be suggested, therefore, that before the eutopic endometrium infiltrates the myometrium, pelvic peritoneum or ovaries, it may have acquired special characteristics that are different from normal endometrium.
The present study provides further evidence in answer to the question of whether Comparison of the peak intensities found using protein chip technology coupled with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for mitochondrial proteins where a significant difference was found between eutopic endometrium samples from women with endometriosis and those from controls Mitochondrial proteins in adenomyosis and endometriosis adenomyosis is a variant of endometriosis or a disease that is distinct from endometriosis. In the present study, 82 protein peaks were found in individuals with adenomyosis and 78 were found in patients with endometriosis; 14 of these proteins peaks were common to both groups, although 13 showed no significant difference in intensity between the groups. In previous studies, some proteins were found to be dysregulated in both adenomyosis and endometriosis. 8 -11 It has also been indicated that adenomyosis and endometriosis are associated with various autoimmune phenomena. 20 These clues might indicate that adenomyosis and endometriosis have similar changes in mitochondrial proteins in eutopic endometrium but that not all the changes are the same. Adenomyosis is a special kind of endometriosis and has its own distinct characteristics. Further identification of these proteins may lead to improved explanations of the mechanism involving eutopic endometrium in adenomyosis and endometriosis.
Future planned work includes identification of the mitochondrial proteins or peptides to elucidate further the pathology and detection of eutopic endometrium in adenomyosis and endometriosis. Research in vitro and in animal models can also be used to detect the variances in mitochondrial proteins at different levels. Further study will assist in the eventual development of new diagnoses and treatments for adenomyosis and endometriosis.
In conclusion, compared with healthy control patients, there are differences in the mitochondrial proteins isolated from the eutopic endometrium of patients with adenomyosis and endometriosis. Although the changes in mitochondrial proteins in eutopic endometrium from patients with adenomyosis and endometriosis were largely similar, significant differences could also be detected. Further identification of these proteins and elucidation of the differences will help towards the differential diagnosis of adenomyosis and endometriosis and new therapeutic approaches.
